Drug Trial Radar · NCT04878471
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants
Last checked: Nov 20, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Jun 2, 2021
Primary completion
Jul 22, 2021
Study completion Jul 22, 2021
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- May 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- Male only, from 20 years, up to 44 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single intravenous doses of ASP5354 in healthy, adult Japanese male participants.
Conditions
- Healthy Volunteers
Interventions
Pudexacianinium chlorideDrug
Intravenous
PlaceboDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs)Time frame: Up to 6 days
- Number of participants with laboratory value abnormalities and/or adverse events (AEs)Time frame: Up to 6 days
- Number of participants with vital sign abnormalities and/or adverse events (AEs)Time frame: Up to 6 days
- Number of participants with routine 12-lead electrocardiogram (ECG) abnormalities and/or adverse events (AEs)Time frame: Up to 6 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
JP81001
Sumida-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.